Big Alliances a Prerequisite for Big Market Caps in Diagnostics
Since 1990, only four diagnostic companies have breached the $100 million company valuation mark with their initial public offerings. Two factors which seem to be the common thread: Innovative technology and major alliances with larger, well-established companies.
You may also be interested in...
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.